• Wed, July 31, 2024

Matt O"Brien Maintained (ATRC) at Buy with Decreased Target to $40 on, Jul 31st, 2024

Matt O"Brien of Piper Sandler, Maintained "AtriCure, Inc." (ATRC) at Buy with Decreased Target from $65 to $40 on, Jul 31st, 2024.

Matt has made no other calls on ATRC in the last 4 months.

There are 2 other peers that have a rating on ATRC. Out of the 2 peers that are also analyzing ATRC, 0 agree with Matt"s Rating of Hold.

These are the ratings of the 2 analyists that currently disagree with Matt;

William Plovanic of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $49 on, Thursday, May 2nd, 2024
Suraj Kalia of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $32 on, Tuesday, April 23rd, 2024


Like: 👍